Deciphera Pharmaceuticals, Inc. (DCPH)
Deciphera Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $25.59, up 0.08% on the session, giving a market capitalisation of $2.21B. On trailing twelve-month figures it carries a trailing P/E of -11.17, a net margin of -119.3%. Its beta of 0.18 implies it has historically moved less than the broad market.
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally. The company's flagship product, QINLOCK, is employed in the treatment of gastrointestinal stromal tumors (GIST) and is additionally undergoing a Phase 3 clinical trial (INTRIGUE study) for second-line GIST. Deciphera's pipeline also includes vimseltinib, a potent, orally available, and highly selective switch-control kinase inhibitor targeting colony stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT). Furthermore, they are advancing DCC-3116, currently in preclinical development, which targets RAS/RAF mutant cancers. Established in 2003, Deciphera Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Deciphera Pharmaceuticals, Inc. is most often compared with the following Healthcare names: